Biogen Inc. (BIIB.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
At close: 01:55PM CST
| Previous close | 3,450.00 |
| Open | 3,411.70 |
| Bid | 3,394.81 x 100 |
| Ask | 0.00 x 100 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 74 |
| Market cap | 502.31B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 25.38 |
| EPS (TTM) | 135.93 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
© 2024 Yahoo. All rights reserved.